Editorial on the "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial," which studied optimal medical treatment with or without percutaneous coronary intervention (PCI) for stable coronary disease.
"Just as a failure to treat a potentially lethal prostate cancer is generally considered inappropriate from a quality-of-care perspective, overtreatment of lower-risk cancers is also not in the patient's best interest"...